Wedbush Lifts Earnings Estimates for Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Stock analysts at Wedbush raised their Q1 2025 EPS estimates for shares of Apellis Pharmaceuticals in a report issued on Monday, March 3rd. Wedbush analyst L. Chico now forecasts that the company will earn ($0.43) per share for the quarter, up from their previous estimate of ($0.50). Wedbush currently has a “Neutral” rating and a $29.00 price target on the stock. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share. Wedbush also issued estimates for Apellis Pharmaceuticals’ Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.33) EPS, FY2025 earnings at ($1.51) EPS, FY2026 earnings at ($0.87) EPS, FY2027 earnings at $1.04 EPS and FY2028 earnings at $2.28 EPS.

APLS has been the topic of several other research reports. Royal Bank of Canada dropped their price target on shares of Apellis Pharmaceuticals from $26.00 to $25.00 and set a “sector perform” rating on the stock in a research note on Monday. Bank of America dropped their price target on shares of Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. JPMorgan Chase & Co. raised their target price on shares of Apellis Pharmaceuticals from $50.00 to $54.00 and gave the company an “overweight” rating in a research note on Tuesday. The Goldman Sachs Group lowered their target price on shares of Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating on the stock in a research note on Monday. Finally, Scotiabank lowered their target price on shares of Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating on the stock in a research note on Wednesday, November 6th. Eight analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $45.53.

Apellis Pharmaceuticals Stock Performance

Shares of APLS opened at $26.00 on Wednesday. The company’s fifty day moving average is $29.53 and its 200-day moving average is $31.30. Apellis Pharmaceuticals has a 12 month low of $23.77 and a 12 month high of $64.33. The firm has a market cap of $3.23 billion, a price-to-earnings ratio of -12.81 and a beta of 0.93. The company has a quick ratio of 3.73, a current ratio of 4.36 and a debt-to-equity ratio of 1.91.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Friday, February 28th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.08. Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The company had revenue of $212.50 million during the quarter, compared to the consensus estimate of $197.92 million. During the same quarter in the prior year, the firm earned ($0.73) EPS. The company’s revenue was up 45.2% compared to the same quarter last year.

Insider Buying and Selling at Apellis Pharmaceuticals

In other news, insider Caroline Baumal sold 2,816 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $33.81, for a total transaction of $95,208.96. Following the completion of the transaction, the insider now directly owns 55,560 shares of the company’s stock, valued at approximately $1,878,483.60. This trade represents a 4.82 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Nur Nicholson sold 2,145 shares of the firm’s stock in a transaction dated Friday, January 17th. The stock was sold at an average price of $29.96, for a total transaction of $64,264.20. Following the transaction, the insider now directly owns 52,011 shares of the company’s stock, valued at $1,558,249.56. The trade was a 3.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 60,365 shares of company stock valued at $1,810,479 in the last ninety days. Company insiders own 6.80% of the company’s stock.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. Toronto Dominion Bank lifted its holdings in Apellis Pharmaceuticals by 3,791.4% during the 4th quarter. Toronto Dominion Bank now owns 997,053 shares of the company’s stock valued at $31,816,000 after purchasing an additional 971,431 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in Apellis Pharmaceuticals during the 4th quarter valued at about $83,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Apellis Pharmaceuticals by 11.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 212,887 shares of the company’s stock valued at $6,793,000 after purchasing an additional 21,822 shares during the last quarter. Woodline Partners LP lifted its holdings in Apellis Pharmaceuticals by 0.5% during the 4th quarter. Woodline Partners LP now owns 189,477 shares of the company’s stock valued at $6,046,000 after purchasing an additional 913 shares during the last quarter. Finally, Vident Advisory LLC bought a new position in Apellis Pharmaceuticals during the 4th quarter valued at about $465,000. 96.29% of the stock is owned by institutional investors.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).